Carisma Therapeutics Inc. CARM
0.00
0.00
NaN
as of 25 Sep
- Market cap
- $1.5M
- P/E
- 0.0×
Follow CARM
Growth Flags
show if company had growth for consecutive years
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
24.88 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.40 | 0.72 | — | — | 3.88 | 3.93 | 2.77 | 6.38 | 0.89 |
P/FCF ratio |
14.66 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(7.49) | (5.98) | — | — | (18.76) | (11.79) | (1.59) | (5.91) | (2.08) |
P/B ratio |
1.08 | 1.20 | — | — | 0.00 | 0.87 | 0.00 | 3.59 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | — | — | 0.00 | 1.03 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.56 | 0.24 | — | — | 2.54 | (0.37) | 1.00 | 1.20 | (0.02) |
EV/EBITDA |
5.50 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
EV/Operating CF |
6.59 | (0.40) | — | — | (3.38) | 0.20 | (1.91) | (0.22) | 0.01 |
EV/FCF |
5.85 | (0.40) | — | — | (3.37) | 0.20 | (1.00) | (0.22) | 0.01 |
Quick Ratio |
6.37 | 3.11 | 8.25 | 5.65 | 3.07 | 16.18 | 2.69 | 4.88 | 1.12 |
Current Ratio |
6.51 | 3.17 | 8.47 | 6.39 | 3.48 | 17.77 | 2.78 | 5.06 | 1.48 |
Net Debt/EBITDA |
(8.33) | 0.51 | 1.47 | 0.44 | 2.64 | (7.00) | 0.34 | 0.91 | 0.30 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 47.94% | 0.37% | 0.07% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.24) | 0.01 | 0.00 |
Asset Turnover |
0.43 | 0.00 | 0.00 | 0.00 | 0.09 | 0.15 | 0.06 | 0.18 | 0.33 |
Operating CF/Net income |
1.34 | 0.61 | 0.68 | 0.35 | 1.37 | 204.99 | 0.08 | 0.93 | 0.99 |
Capex/Depreciation |
1.83 | 0.34 | (0.01) | (0.62) | (0.07) | 0.00 | (1.05) | (0.27) | (0.04) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 6.56% | (102.38%) | (108.27%) | (1,228.08%) | 125.50% | (0.41%) | (421.67%) | 149.61% | 8,783.88% | |
| 2.68% | (32.40%) | (36.10%) | (95.16%) | (19.01%) | (0.18%) | (39.13%) | (107.45%) | (100.78%) | |
ROIC |
13.43% | (545.15%) | 0.00% | 0.00% | 0.00% | (58.88%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
8.31% | (269.21%) | (73.30%) | (232.85%) | (50.16%) | (0.17%) | (140.59%) | (121.80%) | (497.55%) |
Average Days of Receivables |
0.00 | 0.00 | — | — | 0.00 | 336.80 | 30.62 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
44.96% | 2,943.53% | 0.00% | 0.00% | 259.80% | 95.36% | 575.74% | 496.85% | 303.96% |
Selling, General and Administrative Expense of Revenue |
49.15% | 1,898.82% | 0.00% | 0.00% | 127.29% | 110.73% | 95.36% | 197.90% | 112.76% |
Intangible Assets out of Total Assets |
0.74 | 0.79 | 0.53 | 0.52 | 0.48 | 0.12 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
13.39% | 324.94% | 0.00% | 0.00% | 15.64% | 19.38% | 2.80% | 15.52% | 18.59% |
Graham Net Nets |
(0.94) | (1.94) | — | — | (0.43) | 0.92 | (5.89) | 0.18 | (1.98) |
Graham Number |
36.34 | 0.00 | — | — | 12.71 | 0.00 | 208.33 | 0.00 | 4.70 |
Earnings Yield |
4.02% | (137.35%) | — | — | (17.04%) | (12.27%) | (225.13%) | (122.18%) | (347.88%) |
Free Cash Flow Yield |
6.82% | (81.54%) | — | — | (19.41%) | (46.36%) | (35.95%) | (86.45%) | (344.83%) |
Revenue per Share |
28.44 | 0.33 | 0.00 | 0.00 | 1.90 | 2.91 | 4.62 | 0.45 | 0.47 |
Operating CF per Share |
2.41 | (13.61) | (7.39) | (8.25) | (5.22) | (7.56) | (2.40) | (2.42) | (1.45) |
Capex per Share |
0.31 | 0.08 | 0.00 | (0.03) | 0.00 | 0.00 | (2.19) | (0.03) | 0.00 |
Free Cash Flow per Share |
2.72 | (13.53) | (7.39) | (8.28) | (5.22) | (7.56) | (4.59) | (2.46) | (1.45) |
Cash per Share |
24.04 | 11.25 | 16.32 | 10.58 | 9.37 | 17.84 | 24.43 | 2.31 | 0.43 |
Shareholders Equity per Share |
36.69 | 13.82 | 14.31 | (5.87) | (1.56) | 18.84 | (67.04) | 0.79 | (0.67) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
36.69 | 13.82 | 14.31 | (5.87) | (1.56) | 18.84 | (67.04) | 0.79 | (0.67) |
Free Cash Flow |
2.86 | (17.67) | (22.83) | (37.66) | (30.84) | (68.88) | (9.78) | (82.31) | (60.04) |
Working Capital |
21.95 | 10.26 | 45.64 | 45.93 | 44.82 | 194.04 | 34.92 | 64.56 | 7.77 |
Capital Expenditures |
0.33 | 0.10 | 0.00 | (0.14) | (0.01) | 0.00 | (4.66) | (1.13) | (0.12) |
Net Current Asset Value |
(39.49) | (42.08) | (15.60) | (86.62) | (69.18) | 136.57 | (160.23) | 17.45 | (34.54) |
EV/EBIT |
5.84 | 0.00 | — | — | 0.00 | 1.63 | 0.00 | 0.00 | 0.01 |
Capex to Sales |
(0.01) | (0.23) | 0.00 | 0.00 | 0.00 | 0.00 | 0.47 | 0.08 | 0.01 |
Net Profit Margin |
6.31% | (6,830.35%) | 0.00% | 0.00% | (200.64%) | (1.27%) | (622.60%) | (582.34%) | (308.05%) |
Price to Operating Income |
14.64 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.22 | 0.55 | 0.65 | 0.92 | 0.99 | 739.19 | 0.51 | 0.61 | 0.76 |
Cash ROIC |
2.72% | (55.90%) | (24.46%) | (176.27%) | (67.07%) | (20.61%) | 24.51% | (84.18%) | 644.31% |
Accounts Receivable Turnover |
0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.78 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — |
Average Receivables |
— | — | — | — | — | — | 12.66 | — | — |
Average Payables |
1.46 | 1.29 | 1.14 | 1.63 | 2.50 | 2.98 | 2.29 | 2.83 | 3.01 |
Average Assets |
70.46 | 89.60 | 93.33 | 112.96 | 118.59 | 181.79 | 156.45 | 80.85 | 60.01 |
Average Common Equity |
28.81 | 28.36 | 31.12 | 8.75 | (17.96) | 81.24 | 14.52 | (58.07) | (0.69) |
Columns are period end dates